242 related articles for article (PubMed ID: 15758133)
21. [Characteristics of the fibrinolytic system in the newborn].
Schlegel N; Hurtaud-Roux MF; Beaufils F
Ann Pediatr (Paris); 1993 Feb; 40(2):70-4. PubMed ID: 8457135
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion.
Shlansky-Goldberg R
Thromb Res; 2008; 122 Suppl 3():S16-9. PubMed ID: 18760830
[TBL] [Abstract][Full Text] [Related]
23. [Staphylokinase--a specific plasminogen activator].
Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
[TBL] [Abstract][Full Text] [Related]
24. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
26. Comparative lytic efficacy of rt-PA and ultrasound in porcine versus human clots.
Huang S; Shekhar H; Holland CK
PLoS One; 2017; 12(5):e0177786. PubMed ID: 28545055
[TBL] [Abstract][Full Text] [Related]
27. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
28. Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.
Blinc A; Planinsic G; Keber D; Jarh O; Lahajnar G; Zidansĕk A; Demsar F
Thromb Haemost; 1991 May; 65(5):549-52. PubMed ID: 1871717
[TBL] [Abstract][Full Text] [Related]
29. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
Bookstein JJ; Saldinger E
Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
[TBL] [Abstract][Full Text] [Related]
30. [Effectiveness of acylated thrombolytic agents in lysis of blood plasma clots from humans and various animals].
Aĭsina RB; Bashkov GV; Eremeev NL; Popova GIu; Kazanskaia NF
Ukr Biokhim Zh (1978); 1991; 63(2):31-9. PubMed ID: 1882461
[TBL] [Abstract][Full Text] [Related]
31. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
32. Extraction of plasminogen activator in the rat's submaxillary gland.
Lucas ON; Lucas GV
Acta Physiol Pharmacol Ther Latinoam; 1995; 45(2):115-22. PubMed ID: 8580523
[TBL] [Abstract][Full Text] [Related]
33. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
Doolittle RF; Pandi L
Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
[TBL] [Abstract][Full Text] [Related]
34. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
[TBL] [Abstract][Full Text] [Related]
35. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
[TBL] [Abstract][Full Text] [Related]
36. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
37. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
38. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
39. [The potential thrombolysis under selective infusion of the autologous plasmin (AP) solution].
Mizutani M
Hokkaido Igaku Zasshi; 1988 Mar; 63(2):269-76. PubMed ID: 2968301
[TBL] [Abstract][Full Text] [Related]
40. Fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom.
Wang YW; Liang XX; Chen JS; Chen Q; Qiu PX; Lin X; Yan GM
Acta Pharmacol Sin; 2005 Jun; 26(6):691-5. PubMed ID: 15916735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
